Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Navidea Biopharmaceuticals Inc (NAVB)

Navidea Biopharmaceuticals Inc (NAVB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 47,356
  • Shares Outstanding, K 30,163
  • Annual Sales, $ 920 K
  • Annual Income, $ -10,720 K
  • 60-Month Beta 1.67
  • Price/Sales 51.43
  • Price/Cash Flow N/A
  • Price/Book 7.92
Trade NAVB with:

Options Overview

Details
  • Implied Volatility 157.65%
  • Historical Volatility 34.78%
  • IV Percentile 71%
  • IV Rank 26.59%
  • IV High 395.28% on 01/27/21
  • IV Low 71.60% on 05/10/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 15
  • Volume Avg (30-Day) 89
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 757
  • Open Int (30-Day) 1,756

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.09
  • Number of Estimates 1
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +30.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5000 +4.67%
on 09/17/21
1.7300 -9.25%
on 09/07/21
-0.0200 (-1.26%)
since 08/17/21
3-Month
1.4900 +5.37%
on 06/23/21
2.0400 -23.04%
on 06/18/21
-0.4100 (-20.71%)
since 06/17/21
52-Week
1.4600 +7.53%
on 05/14/21
3.1500 -50.16%
on 02/09/21
-1.2200 (-43.73%)
since 09/17/20

Most Recent Stories

More News
Navidea Biopharma (NAVB) Reports Q2 Loss, Misses Revenue Estimates

Navidea (NAVB) delivered earnings and revenue surprises of 0.00% and -56.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

NAVB : 1.5700 (+0.64%)
Navidea Biopharmaceuticals Reports Second Quarter 2021 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its...

NAVB : 1.5700 (+0.64%)
Navidea Biopharmaceuticals to Host Second Quarter 2021 Earnings Conference Call and Business Update

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it...

NAVB : 1.5700 (+0.64%)
Navidea Biopharmaceuticals Announces First 110 Subjects Imaged in NAV3-35 Normative Database Phase 2b Study to Support Rheumatoid Arthritis Indications

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that...

NAVB : 1.5700 (+0.64%)
Navidea Biopharmaceuticals Announces End-of-Phase 2 Type B Meeting Request Granted by the FDA to Discuss Ongoing Clinical Program in Rheumatoid Arthritis

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that...

NAVB : 1.5700 (+0.64%)
Macrophage Therapeutics, Inc. Wins Delaware Case Against Michael Goldberg for Breach of Fiduciary Duty

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that...

NAVB : 1.5700 (+0.64%)
Navidea Biopharmaceuticals Announces Issuance of U.S. Patent for Diagnosis and Treatment of Viral Infections

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that...

NAVB : 1.5700 (+0.64%)
Navidea Biopharmaceuticals Reports First Quarter 2021 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its...

NAVB : 1.5700 (+0.64%)
Navidea Biopharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 11, 2021 / Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 11, 2021 at...

NAVB : 1.5700 (+0.64%)
Navidea Biopharmaceuticals Announces NIH Grant Award to UC San Diego for Clinical Study Evaluating Tc99m Tilmanocept as a Kidney Imaging Agent

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the...

NAVB : 1.5700 (+0.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents for diseases such as cancer and Alzheimer. The Company's radiopharmaceutical development programs include: Lymphoseek(R), AZD4694 and...

See More

Key Turning Points

3rd Resistance Point 1.7133
2nd Resistance Point 1.6567
1st Resistance Point 1.6133
Last Price 1.5700
1st Support Level 1.5133
2nd Support Level 1.4567
3rd Support Level 1.4133

See More

52-Week High 3.1500
Fibonacci 61.8% 2.5044
Fibonacci 50% 2.3050
Fibonacci 38.2% 2.1056
Last Price 1.5700
52-Week Low 1.4600

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar